Rallybio Co. (NASDAQ:RLYB) Receives Consensus Rating of “Moderate Buy” from Analysts

Rallybio Co. (NASDAQ:RLYB) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $9.75.

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Rallybio in a report on Tuesday, December 3rd.

Institutional Investors Weigh In On Rallybio

A number of hedge funds have recently made changes to their positions in RLYB. Hsbc Holdings PLC purchased a new stake in Rallybio during the second quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Rallybio during the 2nd quarter worth approximately $61,000. Acadian Asset Management LLC raised its holdings in shares of Rallybio by 116.3% in the 2nd quarter. Acadian Asset Management LLC now owns 67,695 shares of the company’s stock worth $89,000 after purchasing an additional 36,401 shares during the period. Almitas Capital LLC purchased a new position in Rallybio in the second quarter valued at approximately $135,000. Finally, Geode Capital Management LLC grew its holdings in Rallybio by 11.4% during the third quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after purchasing an additional 24,980 shares during the period. 90.34% of the stock is currently owned by institutional investors.

Rallybio Trading Down 0.7 %

Rallybio stock opened at $0.91 on Friday. The firm has a market capitalization of $37.92 million, a price-to-earnings ratio of -0.57 and a beta of -1.55. The firm’s fifty day moving average price is $1.03 and its two-hundred day moving average price is $1.16. Rallybio has a 1-year low of $0.84 and a 1-year high of $3.46.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.